A new alternative! The Gamaleya Center, a drug producer in Russia, announced today December 29 that it will launch its anti nasal administration vaccine COVID Sputnik in the first quarter of 2022.
“The Sputnik nasal vaccine will be supplied to the market in the first quarter of 2022,” the center reported on its official Twitter account.
According to the Gamaleya Center, the nasal vaccine, the development of which Russia reported in the middle of this year, “will be especially effective against the highly contagious omicron variant, since Not only will it protect against infection, it will prevent transmission. “
The President of Russia, Vladimir Putin, who participated last November in the trials of the nasal preparation, highlighted yesterday that the two-dose Russian COVID vaccine Sputnik V is highly effective against the omicron variant and stated that “it guarantees about 90% protection.”
Until now, Sputnik V has been approved for use in more than 70 countries and 21 other states also gave their go-ahead to Sputnik Light.
The creators of the Russian vaccine argue that at the moment there is no need to develop a new drug for the omicron variant.